Date:

* RECEIVED CENTRAL FAX CENTER

DEC 1 5 2008

This facsimile ressage and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON&BIRD LLP

3201 Beechleaf Court, Suite 600 Raleigh, NC 27604-1062 919-862-2200 Fax: 919-862-2260



TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

December 15, 2008	•	
Recipient;	Company:	
Examiner Anne R. Kubelik	US Patent & Trademark Office Art Unit 1638	
Fax Number:	Voice Number:	
571 -2 73 -8300	5761-272-0801	
Sender:		
Destiny M. Davenport		
Re: Interv ew with Examiner 12/16/08 U.S. Utility Application for AXMI- Gene and Methods for Its Use Appl. No. 10/782,570; Filed Febru Our F 1e 045600/274144	007, A Delta-Endotoxin	
Numl	her of Pages: (including cover page) 2	
IF NOT RECEIVED PROPERLY, PLEA	ASE NOTIFY US IMMEDIATELY AT 919-862-222	<u> </u>
USER CODE: DAVEN	REQUESTED BY: Nora C. Martinez	_ _
CLIENT/MATTER: 045600/274144	OPERATOR:	

CENTRAL FAX CENTER

ALSTON&BIRD LLP

DEC 1 5 2008

TO:

Examiner Anne R. Kubclik (571-272-0801)

Art Unit 1638

FROM: Destiny M. Davenport

DATE: December 15, 2008

RE:

J.S. Utility Application for AXMI-007, A Delta-Endotoxin

Gene and Methods for Its Use

Appl. No. 10/782,570; Filed February 19, 2004

Our File 045600/274144

This memorandum is sent to set forth the attendees and bullet points for discussion at the personal interview to be held at your office on Tucsday, December 16, 2008 at 2:00 p.m.

Attendecs will be:

Destiny M Davenport, Patent Agent W. Murray Spruill, Attorney Nicholas Duck, Inventor Brian Var de Berg, Inventor

Anne R. Kubelik, Examiner

Points to be discussed:

Discuss written description and enablement rejections of variant sequences.

DMD:ncm

Destiny M. Davenport

W Murray Spruill

LEGAL02/31057702v1